NCT05021484View on ClinicalTrials.gov

Felzartamab in Late Antibody-Mediated Rejection

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 6, 2021

Primary Completion Date

March 7, 2024

Study Completion Date

March 7, 2024

Conditions
Antibody-mediated Rejection
Interventions
DRUG

Felzartamab

Intravenous infusion in regular intervals over 6 months

DRUG

Placebo

Intravenous infusion in regular intervals over 6 months

Trial Locations (2)

1090

Medical University of Vienna, Vienna

10117

Charité University, Berlin

Sponsors

Collaborators (1)

Biogen
All Listed Sponsors
collaborator

Charite University, Berlin, Germany

OTHER

collaborator

University of Alberta

OTHER

collaborator

Biogen

INDUSTRY

lead

Farsad Eskandary

OTHER